Linkage disequilibrium between the CYP2C192,17 and CYP2C91 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene–gene interactions on warfarin therapy

• Published in: Journal of thrombosis and thrombolysis 2017, Vol.43 (1), p.124-129
• Main Authors: Khalighi, Koroush, Cheng, Gang, Mirabbasi, Seyedabbas, Khalighi, Bahar, Wu, Yin, Fan, Wuqiang
• Format: Article
• Language: English
• Subjects: Adult; Aged; Alleles; Cardiology; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P-450 CYP2C9 - genetics; Dose-Response Relationship, Drug; Epistasis, Genetic; Female; Hematology; Humans; Linkage Disequilibrium - genetics; Male; Medicine; Medicine & Public Health; Middle Aged; Polymorphism, Single Nucleotide; Vitamin K Epoxide Reductases - genetics; Warfarin - administration & dosage
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-016-1436-2

Warfarin therapy is complicated by its large inter-individual and intra-individual variability. Both genetic and non-genetic factors can affect warfarin therapy. This study aims to investigate the allele distribution of VKORC1, CYP2C9 and CYP2C19 , contribution of different allele variants and possible gene–gene interaction on warfarin therapy. Four hundreds and ninety-two patients were enrolled and single nucleotide polymorphisms for vitamin K epoxide reductase complex subunit 1 ( VKORC1 ), cytochrome P450 CYP2C9 and cytochrome P450 CYP2C19 were genotyped. CYP2C9*1 allele is in complete linkage disequilibrium with CYP2C19 * 2 and CYP2C19*17 (D′ = 1) in our study population. Patient with VKORC1-1639 G  >  A, CYP2C9 * 2 and CYP2C9 * 3 genetic variants need significant lower warfarin dose than patient with wild type allele of VKORC1 1639 G or CYP2C9 * 1 . There is no significant differences between CYP2C19 allele variants for warfarin stable dose and INR > 5 event. Because of the complete linkage disequilibrium between CYP2C19 * 2 ,* 17 and CYP2C9 * 1 , patient with CYP2C19 * 2 /* 2 , * 2 /* 17 and * 17 /* 17 genotypes tend to have higher warfarin dose than patient with CYP2C19 * 1 /* 1 genotype. Stepwise regression analysis showed that VKORC1, CYP2C9 , body mass index (BMI), age and gender were included as a factor significantly contributing to warfarin dose, whereas CYP2C19 did not contribute to warfarin dose. No statistically significant interaction between CYP2C9 and VKORC1 on warfarin dose and INR > 5 event was detected in univariate general linear model analysis. Our study suggests that polymorphic variants of VKORC1 and CYP2C9 affect warfarin dose independently, whereas CYP2C19 did not contribute to warfarin therapy.